Rheumatoid Arthritis
Conditions
Brief summary
The purpose of this study is to use magnetic resonance imaging (MRI) and high-resolution peripheral quantitative computed tomography (HR-pQCT) techniques to look at the damage and disease activity progression in the hand and wrist joints of patients with rheumatoid arthritis. The central hypothesis is that ongoing erosions and cartilage loss in rheumatoid arthritis are due to persistent inflammation, which is poorly detected by clinical examination and markers of systemic inflammation.
Interventions
DRUGCimzia
For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen. After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen.
DEVICEMagnetic Resonance Imaging (MRI)
MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
Sponsors
University of California, San Francisco
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
The inclusion criteria for all patients to be enrolled are: * RA by 2010 ACR classification criteria * Age ≥ 18 years at enrollment * Ability to give consent and follow the study protocol * Prednisone permitted in doses ≤10 mg daily * Women of reproductive potential must agree to use an acceptable method of birth control during treatment Additional inclusion criteria for group I: * DAS28 ≤ 3.2 during the last 2-months prior to the baseline visit * On MTX at a stable dose for \> 8 weeks prior to the baseline visit * No biologic therapy during the past 6-months prior to the baseline visit * No anticipated biologic therapy Additional inclusion criteria for group II: * DAS28 \> 3.2 * No biologic therapy during the past 6-months prior to the baseline visit * Scheduled to initiate anti-TNF therapy using CIMZIA
Exclusion criteria
for all patients to be enrolled are: * Any psychiatric disorder that prevents the subject from providing informed consent * Inability or unwillingness to follow the protocol * Estimated glomerular filtration rate (eGFR, calculated based on serum creatinine) \< 60 ml/min/1.72m2 * Known allergy or hypersensitivity to any study products (including gadolinium) * History of injury or surgery of the wrist and hand to be scanned * Inability to place non-dominant hand appropriately for imaging * History of claustrophobia; inability to tolerate MRI and other contraindication of MRI * Pregnancy or breast-feeding * Diabetes mellitus requiring insulin therapy * Prednisone dose \> 10 mg/day (or equivalent dose of another corticosteroid) within 1 month of baseline visit * Any investigational agent within the earlier of 4 weeks or 5 half-lives prior to randomization * Any biologic therapy within 6-month prior to the baseline visit * Any condition or treatment, which in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the study Additional
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To better understand how Cimzia and methotrexate affect the damage and disease activity progression in the hand and wrist of patients with rheumatoid arthritis | up to 2 years |
Countries
United States
Outcome results
None listed